The Medicines and Healthcare products Regulatory Agency (MHRA) has approved extensions to expiry dates for batches of ALK’s Jext adrenaline auto-injector. This move follows shortages of adrenaline auto-injectors as a result of manufacturing supply-chain issues with Mylan’s Epipen, which last month also received license to temporarily extend expiry dates on its products.
The extensions apply to 32 batches of Jext products, and 9 batches of Epipens, with label expiry dates between July and November 2018. These will all be extended by 4 months to ease the resupply issues. The associated guidance from the Department of Health and Social Care (DHSC) directs clinicians to avoid replacing patient’s devices while they are still within the 4 month extension period.